Analytical Data
-
Gene name
PIGR
- Application
-
Alternative Names
Polymeric Immunoglobulin Receptor; PIgR; Poly-Ig Receptor; Hepatocellular Carcinoma-Associated Protein TB6; PIGR
-
Species
Human
-
Source
HEK293
-
Tag
C-Twin-Strep
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01833
-
Expression Region
K19-R603
-
Molecular Weight
80-100 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PIGR, or polymeric immunoglobulin receptor, is a pivotal protein involved in the transport of immunoglobulins (particularly IgA and IgM) across epithelial cells, playing a crucial role in mucosal immunity. Its significance has garnered extensive scientific interest, especially in the context of understanding immune responses at mucosal surfaces, which are primary entry points for pathogens. Research into PIGR has revealed its potential implications in autoimmune diseases, infections, and even cancer, where dysregulation of immunoglobulin transport can lead to compromised immunity or pathological responses. The advent of recombinant protein technology has enabled researchers to produce PIGR in vitro, facilitating detailed studies on its structure, function, and interactions with immunoglobulins. By generating PIGR as a recombinant protein, scientists aim to investigate its therapeutic potential, assess its role in vaccine development, and explore its application in immunological research. Overall, the study of recombinant PIGR is crucial for advancing our understanding of mucosal immunity and developing novel strategies to combat various diseases.
